The Acute Effect of Vaping on Food Intake

Virginia Commonwealth University (VCU)

Status: Completed

Conditions: Energy Intake; E-Cig Use; Food Intake; Appetite

Treatments: Other: Vaping condition; Other: Control condition

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04219189

HM20018382

2019-066-PBRC (Other Identifier)

U54DA036105 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study assesses the acute effects of a standardized 20-minute vaping episode compared to a non-vaping control condition on ad libitum food intake during a 30-minute buffet meal, occurring approximately 45 minutes after the vaping episode

Full description

Weight control is a common motive for cigarette smoking and nicotine has been shown to suppress appetite and increase resting metabolic rate, and also serves as a behavioral alternative to eating or a distraction from hunger or food craving. Data on the acute effect of e-cigarette use ('vaping') on ad libitum food intake are non-existent. Given that many e-cigarette users report vaping for weight control and that certain e-cigarettes are being actively marketed for weight management and/or suppression of food cravings, addressing this research gap is of the utmost importance.

Enrollment: 40 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 - 65 years of age (ID card verified)
• Reports either everyday e-cigarette use with liquid containing at least 0.3% (~3 mg/ml) nicotine or some day e-cigarette use ( at least 3 days a week) with liquid containing at least 3% (~30 mg/ml) nicotine for the past 30 days.

Exclusion criteria

• being unwilling to consume the foods provided due to: a) dietary limitations or preferences or b) allergies to the foods provided.
• being unwilling to take 20 puffs from a JUUL device containing a 5% nicotine pod
• self-reported current, diagnosed medical condition(s) will be excluded automatically: heart-related conditions (e.g., recent heart attack/stroke, coronary heart disease), severe immune system disorders (e.g., HIV/AIDS, multiple sclerosis), respiratory disorders (e.g., COPD, asthma), kidney diseases, liver diseases (e.g., cirrhosis), or seizures
• observed high blood pressure at screening (systolic >140; diastolic >90)
• other self-reported current, diagnosed medical conditions (e.g., specific food allergies, diabetes, thyroid disease, lyme disease) will be considered for exclusion after consultation with the PI and medical monitor
• self-reported current, diagnosed psychiatric conditions or who report current psychiatric treatment or psychotropic medication use
• past month use of cocaine, opioids, benzodiazepines, methamphetamine, or other (non-cannabis) illicit drugs
• self-report of >25 days out of the past 30 for alcohol use or >20 days out of the past 30 for cannabis use.
• women who are breast-feeding or test positive for pregnancy (by urinalysis at screening)
• women using progestin-IUDS for birth control
• women using birth control injections (e.g., Depo-Provera)
• women who received a hysterectomy and still have ovaries present
• self-report intending to quit tobacco/nicotine products in the next 30 days

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Vaping to Control Group

Experimental group

Description:

Participants in this arm will undergo the vaping condition during the first visit and the control condition during the second visit.

Treatment:

Other: Control condition

Other: Vaping condition

Control to Vaping Group

Experimental group

Description:

Participants in this arm will undergo the control condition during the first visit and the vaping condition during the second visit.

Treatment:

Other: Control condition

Other: Vaping condition